Tevogen Bio Holdings Inc ( TVGN ) shares are trading higher Monday after the company announced an expanded AI collaboration with Microsoft Corp ( MSFT ) .

What Happened: After the market close on Friday, Tevogen Bio ( TVGN ) announced a broadening of its relationship with Microsoft ( MSFT ) to expand its AI-focused collaboration and build its PredicTcell technology. 

The expanded collaboration is expected to use Microsoft’s AI, cloud capabilities and health and life sciences domain expertise to accelerate Tevogen Bio’s target identification and pre-clinical processes.

“As we expand our AI efforts, this broader relationship with Microsoft ( MSFT ) represents a key milestone in our ongoing journey to revolutionize immunotherapy,” said Mittul Mehta, CIO of Tevogen Bio ( TVGN ) and Head of Tevogen.AI.

“Through deeper collaboration with Microsoft ( MSFT ) domain experts, we will further harness the power of AI to bring more precise and personalized treatments to patients at an accelerated pace.”

Tevogen said it will integrate Microsoft’s AI tools into Tevogen.AI to help expand the company’s pre-clinical pipeline and develop algorithms to decode HLA-T cell interactions. The company noted that it will also investigate potential treatments for Human Papillomavirus (HPV).

Tevogen Bio ( TVGN ) is a clinical-stage specialty immunotherapy company using CD8+ cytotoxic T lymphocytes to develop precision T cell therapies for the treatment of infectious diseases, cancers and neurological disorders. PredicTcell is the company’s proprietary technology designed for predictive precision T cell targeting.

See Also: DeepSeek Jitters Shatter US Tech Stocks, Wipe Out $1.2 Trillion On Wall Street: Analyst Eyes Four Chinese Giants Set To Benefit

TVGN Price Action: Tevogen Bio ( TVGN ) shares were up 15.6% at $1.56 at the time of publication Monday, according to Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.